Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Fentanyl-Based Rapid Onset Opioids for the Relief of Breakthrough Cancer Pain: Drug Price Based on Effect Size

  • Seongchul Kim (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Hayoun Jung (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Jina Park (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Jinsol Baek (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Yeojin Yun (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Junghwa Hong (Department of Pharmaceutical Industry, Chung-Ang University) ;
  • Eunyoung Kim (Department of Pharmaceutical Industry, Chung-Ang University)
  • Received : 2022.12.07
  • Accepted : 2023.02.13
  • Published : 2023.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objective: With the advancement of cancer treatments and increased life expectancy, managing breakthrough cancer pain (BTcP) is essential to improve the quality of life for cancer patients. This study aimed to compare the major rapid onset opioids in Korea based on their characteristics and costs to determine the best option for each patient. Methods: Based on sales information from IQVIA-MIDAS, sublingual fentanyl tablet (SLF), fentanyl buccal tablet (FBT), and oral transmucosal fentanyl citrate (OTFC) were selected as the top three drugs for the treatment of BTcP in Korea, considering them the most comparable drugs. The cost and cost-pain relief ratio of the drugs for short-term (1 month) and long-term (1 year) treatment were compared and the ease of administration based on various factors, including pharmacokinetics, onset of action, and administration procedures were evaluated. Results: SLF was evaluated as the best overall in terms of rapid onset of action, ease of administration, and drug cost and also had the highest market share. SLF had the lowest cost pain relief ratio for both the initial and supplemental treatment for the 1-month pain intensity difference 15 (PID15) ratio. However, for the 1-month PID30 ratio, SLF was not superior to OTFC or FBT. The longer the breakthrough cancer pain duration, the more cost-effective the other rapid onset opioids. Conclusion: The rapid onset opioids that fit the patient's breakthrough cancer pain pattern have the best cost-effectiveness.

Keywords

References

  1. National cancer center, cancer trend report 2021. Available from https://cancer.go.kr/download.do?uuid=71610cce-c1a7-457d-8ee6-09c93aacb330.pdf. Accessed February 25, 2023.
  2. Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13(4):331-8. https://doi.org/10.1016/j.ejpain.2008.06.014
  3. Koh S, Lee K, Oh S, Kang J, et al. Assessment, management, and barriers of breakthrough cancer pain: a nationwide study in Korea. Support Care Cancer 2019;27:eP064.
  4. Davies A, Buchanan A, Zeppetella G, et al. Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients. J Pain Symptom Manage. 2013;46(5):619-28. https://doi.org/10.1016/j.jpainsymman.2012.12.009
  5. Bae SB, Lee SC. Medical Treatment of Cancer Pain: Drug Therapy according to Guidelines Will Improve the Quality of Life of Cancer Patients. Korean J Med 2018;93(3):260-5. https://doi.org/10.3904/kjm.2018.93.3.260
  6. Bennett D, Burton AW, Fishman S, Fortner B, et al. Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2 Management. P and T. 2005;30(6):354-61.
  7. HiNeca [Vol.65] Abuse of opioid, are we safe? Available from https://hineca.kr/1976 Accessed November 05 2022.
  8. Min Seok Seo, Jae Yong Shim Breakthrough Cancer Pain. Korean J Hosp Palliat Care 2015;18(1):1-8. https://doi.org/10.14475/kjhpc.2015.18.1.1
  9. IQVIA. Quintiles and IMS Health. Available from https://www.iqvia.com/locations/korea. Accessed February 25, 2023.
  10. Ju, C., Wei, L., Man, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health 2022;7(4):e335-46. https://doi.org/10.1016/S2468-2667(22)00013-5
  11. European Society for Medical Oncology. Cancer Pain Management Clinical Practice Guidelines 2018. Available from https://reference. medscape.com/viewarticle/902352. Accessed February 25, 2023.
  12. Shin J, Shim JY, Seo MS, et al. Factors Influencing Pain Medication Preference for Breakthrough Cancer Patients and Their Application to Treatments: Survey on Physicians. Korean J Hosp Palliat Care 2018;21(1):9-13. https://doi.org/10.14475/kjhpc.2018.21.1.9
  13. Mercadante S, Marchetti P, Cuomo A, Mammucari M, Caraceni A; IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer. 2016;24(2):961-8. https://doi.org/10.1007/s00520-015-2951-y
  14. YS Rhee, SY Kim., JH Park. Financial Hardship Factors affecting the Cancer Patient's Quality of Life. Journal of the Korea Academia-Industrial cooperation Society. 2020;21(10):299-307. https://doi.org/10.5762/KAIS.2020.21.10.299
  15. Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manag. 2014; 10(3):207-15. https://doi.org/10.5055/jom.2014.0209
  16. Cortesi PA, D'Angiolella LS, Vellucci R, et al. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. PLoS One. 2017;12(6):e0179523.
  17. England R, Maddocks M, Manderson C, Zadora-Chrzastowska S, Wilcock A. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care. 2011;1(3):349-51. https://doi.org/10.1136/bmjspcare-2011-000037
  18. Janknegt R, van den Beuken M, Schiere S, et al. Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis. Eur J Hosp Pharm. 2018;25(3):e2.
  19. Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manage. 2014; 47(4):772-85. https://doi.org/10.1016/j.jpainsymman.2013.05.020
  20. Hayan Kwon. Cost-effectiveness analysis of opioid analgesics for treatment of breakthrough pain in cancer patients. M.S Thesis for Seoul National University Graduate School. 2012.
  21. Giuliani J, Fiorica F, Sacchetto A, Franceschini G, Vaccari F, Bonetti A. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. J Oncol Pharm Pract. 2021;27(2):445-7. https://doi.org/10.1177/1078155220983429
  22. Shin J, Cho SJ, Lee J, Choi YS. Validation of the Korean Version of the Breakthrough Pain Assessment Tool in Cancer Patients. J Pain Symptom Manage. 2017;54(3):361-7. https://doi.org/10.1016/j.jpainsymman.2017.07.011
  23. Kwon MY, Cho HN, Koo DH, Lee YG, Oh S, Lee SS. Initial titration with 200 ㎍ fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients. Korean J Intern Med. 2018; 33(3):577-84. https://doi.org/10.3904/kjim.2016.044
  24. Choi YJ Factors associated with Breakthrough Pain in Cancer Patients, M.S Thesis for Kyung Hee University Graduate School. 2019.
  25. Kang JH, Koh SJ, Oh SY, et al. Interference with daily functioning by breakthrough pain in patients with cancer. Support Care Cancer. 2020;28(11):5177-83.  https://doi.org/10.1007/s00520-020-05329-9